


# Palonosetron

Printed from <https://www.cancerquest.org/patients/drug-reference/palonosetron> on 04/26/2026



Brand name: Aloxi®

IUPAC: 3aR)-2-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-1H-benz[de]isoquinolin-1-one

FDA approval: Yes

[Manufacturer Link](#)

Usage:

Palonosetron (Aloxi®) was approved by the FDA in 2003 to help prevent the nausea and vomiting sometimes caused by chemotherapy.<sup>[1](#)</sup>

---

<sup>1</sup> Palonosetron. MedlinePlus. 2016. <https://medlineplus.gov/druginfo/meds/a610002.html>

Mechanism:

Palonosetron is a 5-HT<sub>3</sub> receptor antagonist. It has a strong affinity for this receptor and little for any other type. Blocking this receptor prevents the activation of the vomiting reflex, as it works by blocking serotonin.<sup>[1](#)</sup>

Below is the molecular structure of the 3D conformer Palonosetron.



---

<sup>1</sup> Palonosetron. MedlinePlus. 2016. <https://medlineplus.gov/druginfo/meds/a610002.html>

Side effects:

Common side effects include: headache, fatigue, diarrhea, dizziness, abdominal pain, trouble sleeping and constipation.<sup>[1](#)</sup>

---

<sup>1</sup> Palonosetron. MedlinePlus. 2016. <https://medlineplus.gov/druginfo/meds/a610002.html>